Form 4: RA Capital Management Reports Acquisition of 1,408,450 Shares of 89bio, Inc.

RA Capital Management and related entities report the acquisition of 1,408,450 shares of 89bio, Inc. at a price of $5.325 per share, along with warrants to purchase additional shares.

Summary

• RA Capital Management, L.P., along with related entities including RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund, L.P., filed a Form 4 disclosing changes in beneficial ownership of 89bio, Inc. securities.
• The reported transaction includes the acquisition of 1,408,450 shares of Common Stock at a price of $5.325 per share on April 11, 2024.
• Additionally, warrants to purchase 1,408,450 shares were acquired on the same date.
• RA Capital Management, L.P. serves as the investment manager for RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund, L.P.
• Dr. Peter Kolchinsky and Mr. Rajeev Shah, as managing members of RA Capital Management GP, LLC, disclaim beneficial ownership except to the extent of their pecuniary interest.
• The filing also addresses previously unreported grants of stock options to Dr. Derek DiRocco, a Partner of the Adviser, which were inadvertently not reported due to an administrative error.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The acquisition of shares and warrants signals confidence, but the administrative error and disclaimers temper the overall outlook.

Positives

• The acquisition of shares and warrants indicates a continued investment and confidence in 89bio, Inc. by RA Capital Management.
• The correction of the administrative error regarding stock option grants demonstrates transparency and compliance.

Negatives

• The need to correct a previous administrative error regarding stock option grants could raise minor concerns about internal controls.

Risks

• The disclaimer of beneficial ownership by Dr. Kolchinsky and Mr. Shah, except to the extent of their pecuniary interest, could be interpreted as a cautious approach to their involvement.
• The value of the warrants is dependent on the future performance of 89bio, Inc.'s stock.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by significant shareholders and insiders, providing transparency to the market.

Comparison to Industry Standards

• RA Capital's investment in 89bio is similar to other venture capital and private equity firms investing in biotech companies with promising drug candidates.
• Comparable firms like OrbiMed Advisors and Deerfield Management also frequently file Form 4s reflecting their investment activities in the healthcare sector.
• The size of the investment is within the typical range for institutional investors in a company of 89bio's market capitalization.

Stakeholder Impact

• The increased stake by RA Capital Management could positively influence investor confidence in 89bio, Inc.
• Employees may view the investment as a sign of stability and growth potential.
• The investment could enable 89bio to further develop its pipeline and partnerships.

Key Dates